Evidence map›Paper›PMID 39960744›Full record

ReviewChemistry (Weinheim an der Bergstrasse, Germany)2025

Unlocking Catalysis Using Oxidatively Induced Reductive Elimination.

Carmen Antuña-Hörlein, Jean-Pierre Djukic

Abstract readReview
In one paragraph

Review in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Unlocking Catalysis Using Oxidatively Induced Reductive Elimination.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Carmen Antuña-HörleinLCSOM, Institut de Chimie de Strasbourg, CNRS UMR 7177, Université de Strasbourg, 4 rue Blaise Pascal, 67000, Strasbourg, France.ORCID https://orcid.org/0000-0001-9966-1498
Jean-Pierre DjukicLCSOM, Institut de Chimie de Strasbourg, CNRS UMR 7177, Université de Strasbourg, 4 rue Blaise Pascal, 67000, Strasbourg, France.ORCID https://orcid.org/0000-0003-3196-4921

Funding

Centre National de la Recherche ScientifiqueUniversité de Strasbourg
6 · The paper itself

Abstract

Oxidatively induced reductive elimination (OIRE) has become a crucial chemical process to enable the effective formation of otherwise much less accessible products. The chemically, electrochemically, or photochemically triggered oxidation of appropriate metal complexes leading to a reductive elimination process otherwise chemically unfavorable has long been studied in stoichiometric metal-centered reactions. However, its conscious inclusion and targeted application in catalysis is a rather recent development. Ruthenium and Group 9 metal complexes are particularly representative examples of how the observed OIRE abilities can be modulated using different coupling partners. Parallels can be drawn between rhodium and iridium, which have a long history as efficient catalysts, and their more readily available 3d row metal neighbor, i. e. cobalt, with ruthenium also providing a matching reactivity. This review explores the history of OIRE reactions throughout the last few centuries, highlighting the role of Ti, Mo, Fe, Hg, Ni, Ru and group 9 transition metals as key players in C-H bond functionalization and OIRE chemistry, discussing the most relevant studies published in the field whilst pinpointing research gaps that require new theoretical and mechanistic studies, with the final goal of unlocking the full potential of OIRE chemistry in organometallic homogeneous catalysis.

Indexed as

C−H bond activationOrganometallic catalysisOxidatively induced reductive eliminationTransition metals

Identifiers

PMID39960744
PMCPMC11937881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.